Mollie E Barnard ScD

Assistant Professor, Hematology & Medical Oncology

Center Faculty Member, Slone Epidemiology Center

72 E. Concord Street | (617) 734-6006
Mollie Barnard

Hematology & Medical Oncology


Dr. Barnard is a molecular and genetic epidemiologist whose research focuses on the epidemiology of breast and ovarian cancers. She is especially interested in identifying modifiable factors that contribute to racial and ethnic disparities in breast cancer risk and survival, and characterizing the molecular and genetic etiology of ovarian cancer.


Epidemiology, ScD, Harvard School of Public Health, 2018

Biology, BA, Swarthmore College, 2010

Epidemiology, SM/ScM, Harvard School of Public Health, 2015


Published on 11/4/2022

Lawson-Michod KA, Watt MH, Grieshober L, Green SE, Karabegovic L, Derzon S, Owens M, McCarty RD, Doherty JA, Barnard ME. Pathways to ovarian cancer diagnosis: a qualitative study. BMC Womens Health. 2022 Nov 04; 22(1):430. PMID: 36333689.

Published on 7/19/2022

Blair LK, Warner ET, James P, Hart JE, VoPham T, Barnard ME, Newton JD, Murthy DJ, Laden F, Tamimi RM, DuPre NC. Exposure to natural vegetation in relation to mammographic density in a Massachusetts-based clinical cohort. Environ Epidemiol. 2022 Aug; 6(4):e216. PMID: 35975164.

Published on 7/1/2022

Barnard ME, Martheswaran T, Van Meter M, Buys SS, Curtin K, Doherty JA. Body Mass Index and Mammographic Density in a Multiracial and Multiethnic Population-Based Study. Cancer Epidemiol Biomarkers Prev. 2022 Jul 01; 31(7):1313-1323. PMID: 35511751.

Published on 5/9/2022

Barnard ME, Meeks H, Jarboe EA, Albro J, Camp NJ, Doherty JA. Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study. J Med Genet. 2023 Feb; 60(2):119-127. PMID: 35534206.

Published on 10/8/2019

Manichaikul A, Peres LC, Wang XQ, Barnard ME, Chyn D, Sheng X, Du Z, Tyrer J, Dennis J, Schwartz AG, Cote ML, Peters E, Moorman PG, Bondy M, Barnholtz-Sloan JS, Terry P, Alberg AJ, Bandera EV, Funkhouser E, Wu AH, Pearce CL, Pike M, Setiawan VW, Haiman CA, Palmer JR, LeMarchand L, Wilkens LR, Berchuck A, Doherty JA, Modugno F, Ness R, Moysich K, Karlan BY, Whittemore AS, McGuire V, Sieh W, Lawrenson K, Gayther S, Sellers TA, Pharoah P, Schildkraut JM. Identification of novel epithelial ovarian cancer loci in women of African ancestry. Int J Cancer. 2020 06 01; 146(11):2987-2998. PMID: 31469419.

Published on 8/6/2019

Barnard ME, Beeghly-Fadiel A, Milne GL, Akam EY, Chan AT, Eliassen AH, Rosner BA, Shu XO, Terry KL, Xiang YB, Zheng W, Tworoger SS. Urinary PGE-M Levels and Risk of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1845-1852. PMID: 31387969.

Published on 6/1/2019

Simon TG, Barnard ME, Chan AT. Aspirin Use and the Risk of Cancer-In Reply. JAMA Oncol. 2019 06 01; 5(6):913. PMID: 31046070.

Published on 12/1/2018

Barnard ME, Poole EM, Curhan GC, Eliassen AH, Rosner BA, Terry KL, Tworoger SS. Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies. JAMA Oncol. 2018 12 01; 4(12):1675-1682. PMID: 30286239.

Published on 10/30/2018

Barnard ME, Hecht JL, Rice MS, Gupta M, Harris HR, Eliassen AH, Rosner BA, Terry KL, Tworoger SS. Anti-Inflammatory Drug Use and Ovarian Cancer Risk by COX1/COX2 Expression and Infiltration of Tumor-Associated Macrophages. Cancer Epidemiol Biomarkers Prev. 2018 12; 27(12):1509-1517. PMID: 30377203.

Published on 7/18/2018

Merritt MA, Rice MS, Barnard ME, Hankinson SE, Matulonis UA, Poole EM, Tworoger SS. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. Lancet Oncol. 2018 08; 19(8):1107-1116. PMID: 30029888.

View full list of 19 publications.